Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection

Alexander Solms*, Shadan Lalezari, Anita Shah, Gili Kenet

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e145-e147
JournalHaemophilia
Volume26
Issue number3
DOIs
StatePublished - 1 May 2020
Externally publishedYes

Funding

FundersFunder number
Alnylam
BPL
Bayer
CSL Behring
BioMarin Pharmaceutical

    Cite this